Original Article

You have full text access to this OnlineOpen article

Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer†

  1. Celestia S. Higano MD1,‡,*,
  2. John M. Corman MD2,
  3. David C. Smith MD3,
  4. Arthur S. Centeno MD4,
  5. Christopher P. Steidle MD5,
  6. Marc Gittleman MD6,
  7. Jonathan W. Simons MD7,§,
  8. Natalie Sacks MD8,¶,
  9. Junko Aimi PhD8,¶,
  10. Eric J. Small MD9

Article first published online: 21 JUL 2008

DOI: 10.1002/cncr.23669

Issue

Cancer

Cancer

Volume 113, Issue 5, pages 975–984, 1 September 2008

Additional Information

How to Cite

Higano, C. S., Corman, J. M., Smith, D. C., Centeno, A. S., Steidle, C. P., Gittleman, M., Simons, J. W., Sacks, N., Aimi, J. and Small, E. J. (2008), Phase 1/2 dose-escalation study of a GM-CSF-secreting, allogeneic, cellular immunotherapy for metastatic hormone-refractory prostate cancer. Cancer, 113: 975–984. doi: 10.1002/cncr.23669

Author Information

  1. 1

    Departments of Oncology and Urology, University of Washington, Seattle, Seattle, Washington

  2. 2

    Floyd and Delores Jones Cancer Center, Virginia Mason Medical Center, Seattle, Washington

  3. 3

    Departments of Internal Medicine and Urology, University of Michigan Medical Center, Ann Arbor, Michigan

  4. 4

    Urology San Antonio, San Antonio, Texas

  5. 5

    Northeast Indiana Research, Fort Wayne, Indiana

  6. 6

    South Florida Medical Research, Aventura, Florida

  7. 7

    Winship Cancer Institute, Emory University School of Medicine, Atlanta, Georgia

  8. 8

    Department of Clinical Research, Cell Genesys, Inc, South San Francisco, California

  9. 9

    Comprehensive Cancer Center, University of California, San Francisco, San Francisco, California

  1. ‡

    Fax: (650) 595-0180

  2. §

    J.W. Simons is a coinventor of 2 issued US patents (US Pat. Nos. 7,226,606 and 7,217,421), has pending applications that are exclusively licensed to and co-owned by Cell Genesys, and has received honoraria from Cell Genesys for speaking engagements.

  3. N. Sacks and J. Aimi are employees of Cell Genesys.

*Seattle Cancer Care Alliance, 825 Eastlake Ave. E, P.O. Box 19023, Seattle, WA 98109-1023

  1. †

    All patients provided informed consent.

Publication History

  1. Issue published online: 20 AUG 2008
  2. Article first published online: 21 JUL 2008
  3. Manuscript Accepted: 11 APR 2008
  4. Manuscript Revised: 9 APR 2008
  5. Manuscript Received: 14 DEC 2007

Funded by

  • Cell Genesys, South San Francisco, California, to each investigator

SEARCH

SEARCH BY CITATION

ARTICLE TOOLS

View Full Article (HTML) Get PDF (186K)

REFERENCES

  • 1
    Sanda MG,Ayyagari SR,Jaffee EM. Demonstration of a rational strategy for human prostate cancer gene therapy. J Urol. 1994; 151: 622–628.
  • 2
    Schlom J,Arlen PM,Gulley JL. Cancer vaccines: moving beyond current paradigms. Clin Cancer Res. 2007; 13: 3776–3782.
  • 3
    Simons JW,Carducci MA,Mikhak B, et al. Phase I/II trial of an allogeneic cellular immunotherapy in hormone-naive prostate cancer. Clin Cancer Res. 2006; 12(11 pt 1): 3394–3401.
  • 4
    Small EJ,Schellhammer PF,Higano CS, et al. Placebo-controlledphase III trial of immunologic therapy with sipuleucel-T (APC8015) in patients with metastatic, asymptomatic hormone refractory prostate cancer. J Clin Oncol. 2006; 24: 3089–3094.
  • 5
    Lin AM,Hershberg RM,Small EJ. Immunotherapy for prostate cancer using prostatic acid phosphatase loaded antigen presenting cells. Urol Oncol. 2006; 24: 434–441.
  • 6
    Dipaola R,Plante M,Kaufman H, et al. A phase I trial of pox PSA vaccines (PROSTVAC-VF) with B7-1, ICAM-1, and LFA-3 co-stimulatory molecules (TRICOM) in patients with prostate cancer. J Transl Med. 2006; 4: 1.
  • 7
    Simmons AD,Li B,Gonzalez-Edick M, et al. GM-CSF-secreting cancer immunotherapies: preclinical analysis of the mechanism of action. Cancer Immunol Immunother. 2007; 56: 1653–1665.
  • 8
    Small EJ,Sacks N,Nemunaitis J, et al. GM-CSF-secreting, allogeneic cellular immunotherapy for hormone-refractory prostate cancer. Clin Cancer Res. 2007; 13: 3883–3891.
  • 9
    Jaffee EM,Hruban RH,Biedrzycki B, et al. Novel allogeneic granulocyte-macrophage colony-stimulating factor-secreting tumor vaccine for pancreatic cancer: a phase I trial of safety and immune activation. J Clin Oncol. 2001; 19: 145–156.
  • 10
    Thomas AM,Santarsiero LM,Lutz ER, et al. Mesothelin-specific CD8(+) T cell responses provide evidence of in vivo cross-priming by antigen-presenting cells in vaccinated pancreatic cancer patients. J Exp Med. 2004; 200: 297–306.
  • 11
    Bubley GJ,Carducci M,Dahut W, et al. Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol. 1999; 17: 3461–3467. Erratum in: J Clin Oncol. 2000; 18: 2644.
  • 12
    Green S,Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs. 1992; 10: 239–253.
  • 13
    Agresti A. Categorical Data Analysis, New York: John Wiley; 1990: 100–102.
  • 14
    Kaplan EI,Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53: 457.
  • 15
    Halabi S,Small EJ,Kantoff PW, et al. Prognostic model for predicting survival in men with HRPC. J Clin Oncol. 2003; 21: 1232–1237.
  • 16
    Serafini P,Carbley R,Noonan KA,Tan G,Bronte V,Borrello I. High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res. 2004; 64: 6337–6343.
  • 17
    Tannock IF,de Wit R,Berry WR, et al. Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer. N Engl J Med. 2004; 15: 1502–1512.
  • 18
    [Anonymous Author]. Leukine Sargramostim Package Insert, Revision 0230-03. Richmond, California: Berlex Laboratories; June 2002.
  • 19
    van der Flier A,Sonnenberg A. Structural and functional aspects of filamins. Biochim Biophys Acta. 2001; 1538: 99–117.
  • 20
    Takafuta T,Wu G,Murphy GF,Shapiro SS. Human beta-filamin is a new protein that interacts with the cytoplasmic tail of glycoprotein Ibalpha. J Biol Chem. 1998; 273: 17531–17538.
  • 21
    Sjoblom T,Jones S,Wood LD, et al. The consensus coding sequences of human breast and colorectal cancers. Science. 2006; 314: 268–274.
View Full Article (HTML) Get PDF (186K)